Soluble Urokinase Receptor and Mortality in Kidney Transplant Recipients

Transpl Int. 2022 Feb 3:35:10071. doi: 10.3389/ti.2021.10071. eCollection 2021.

Abstract

Main problem: Soluble urokinase plasminogen activator receptor (suPAR) is an immunological risk factor for kidney disease and a prognostic marker for cardiovascular events. Methods: We measured serum suPAR levels in a total of 1,023 kidney transplant recipients either before (cohort 1, n = 474) or at year 1 after transplantation (cohort 2, n = 549). The association of suPAR levels and all-cause and cardiovascular mortality was evaluated by multivariable Cox regression analysis. Results: The highest suPAR tertile compared to the two lower tertiles had a significantly higher risk of all-cause mortality in both cohorts separately (cohort 1: hazard ratio (HR) 1.92, 95% confidence interval (CI) 1.20-3.08, p = 0.007; cohort 2: HR = 2.78, 95% CI 1.51-5.13, p = 0.001) and combined (n = 1,023, combined HR = 2.14, 95% CI 1.48-3.08, p < 0.001). The association remained significant in the subgroup of patients with normal kidney function (cohort 2: HR = 5.40, 95% CI 1.42-20.5, p = 0.013). The increased mortality risk in patients with high suPAR levels was attributable mainly to an increased rate of cardiovascular death (n = 1,023, HR = 4.24, 95% CI 1.81-9.96, p < 0.001). Conclusion: A high suPAR level prior to and at 1 year after kidney transplantation was associated with an increased risk of patient death independent of kidney function, predominantly from cardiovascular cause.

Keywords: cardiovascular; kidney; mortality; suPAR; transplantation.

MeSH terms

  • Biomarkers
  • Humans
  • Kidney Transplantation* / adverse effects
  • Prognosis
  • Receptors, Urokinase Plasminogen Activator*
  • Urokinase-Type Plasminogen Activator

Substances

  • Biomarkers
  • Receptors, Urokinase Plasminogen Activator
  • Urokinase-Type Plasminogen Activator